Skip to main content

Table 4 Change from Baseline in CGI-BP-S-depression and CGI-BP-S-overall

From: Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

PLO

NA

−0.25 [− 0.38,-0.11]

−0.59 [− 2.06, 0.76]

−0.55 [− 0.68–0.41]

−0.05 [− 0.26, 0.17]

−0.63 [− 0.87,-0.39]

−0.21 [− 0.63, 0.20]

ARI

NA

NA

NA

NA

NA

NA

NA

CAR

−0.34 [− 1.82, 1.01]

−0.30 [− 0.49,-0.11]

0.20 [− 0.05, 0.46]

−0.38 [− 0.66,-0.10]

−0.32 [− 0.72, 0.08]

−0.11 [− 0.68, 0.47]

NA

OLA

0.04 [− 1.31, 1.51]

0.54 [− 0.83, 2.03]

−0.04 [− 1.41, 1.46]

NA

NA

NA

NA

QUE

0.50 [0.24, 0.76]

−0.08 [− 0.36, 0.19]

NA

NA

NA

NA

NA

ZIP

−0.58 [− 0.91,-0.26]

− 0.63 [− 1.12,-0.14]

−0.42 [− 1.06, 0.23]

NA

− 0.31 [− 0.95, 0.33]

NA

NA

LUR

  1. Note: CGI-BP-S-overall are on the top-right and CGI-BP-S-depression results are on the bottom-left. Numbers represent the mean change [95% credible interval]. In the top-right comparisons, the row treatment is the reference category. In the bottom-left, the column treatment is the reference category
  2. Abbreviations: CGI-BP-S Clinical Global Impressions–Bipolar–Severity Scale, PLO Placebo, ARI Aripiprazole, CAR Cariprazine, LUR Lurasidone, OLA Olanzapine, QUE Quetiapine, ZIP Ziprasidone